1yfe Health — Full Investor Report
Corporation: 1YFE Inc. (Ontario, Canada) · Document: Complete Investor Materials · Date: 2026-10-09
This report contains the complete 5-method triangulated valuation analysis, 9-slide investor deck, and 6-year financial model for 1yfe Health (operated by 1YFE Inc.). All figures are internal management estimates based on a full codebase audit and industry benchmarks.
Part I — Company & Round Overview
| Legal Name | 1YFE Inc. |
| Operating Brand | 1yfe Health |
| Tagline | The AI-Powered Peptide Therapy Platform |
| Description | Physician-prescribed, AI-optimized peptide protocols delivered direct-to-patient. Full-stack platform with 40+ modules spanning e-commerce, telemedicine, AI health intelligence, and pharmacy fulfillment. |
| Stage | Pre-Revenue (Platform Complete) |
| Founded | 2025 |
| Jurisdiction | Ontario, Canada |
Round Terms
| Round Type | Seed |
| Raise Amount | $3.00M USD |
| Pre-Money Valuation | $5.50M USD |
| Post-Money Valuation | $8.50M USD |
| Investor Equity | 35.29% |
| Target Runway | 18 months |
| Series A Trigger | $2.0M ARR |
Part II — 5-Method Triangulated Valuation Analysis
Summary Table
| Method | Valuation (USD) |
|---|
| 1. Berkus Method | $1.95M |
| 2. Scorecard Method (Bill Payne) | $4.11M |
| 3. Risk Factor Summation | $4.50M |
| 4. Venture Capital Method (ceiling signal) | $39.50M |
| 5. Cost-to-Duplicate | $3.27M |
| Range Low → High | $1.95M → $39.50M |
| 5-Method Average | $10.67M |
| Round Pre-Money Set At | $5.50M |
2.1 Berkus Method — $1.95M
Assigns up to $500K per success factor. Max $2.5M for pre-revenue startups.
| Factor | Value | Max | Rationale |
|---|
| Sound Idea | $475K | $500K | $68B TAM growing 9.4% CAGR. FDA Category 1 reclassification (Feb 2026) creates legal clarity. Physician-prescribed DTC model validated by Hims/Ro ($1B+ revenue). Near-max score. |
| Prototype / Technology | $475K | $500K | Not a prototype — production-grade platform: 40+ pages, 25 database entities, 30+ backend functions, 3 AI agents, Stripe payments, real-time subscriptions, genetic matching, predictive health engine, wearable integration, community forum, affiliate MLM system, full admin portal. This is a complete product. |
| Quality Management Team | $350K | $500K | Technical founder built the entire platform solo — demonstrates exceptional execution velocity. Medical advisory pipeline active. Needs C-suite hires (CMO, COO, medical director) which is typical pre-revenue. Deducted for solo-founder risk. |
| Strategic Relationships | $375K | $500K | FDA-registered 503A pharmacy partnerships established. IMLC physician network for telehealth prescribing across 43+ states. Affiliate program with multi-tier commission structure built. No enterprise contracts yet — deducted accordingly. |
| Product Rollout / Sales | $275K | $500K | Platform is live and functional with Stripe integration (test mode). 5 subscription tiers priced and configured. Lead capture, health intake forms, and checkout flows built. No reported revenue — pre-launch phase. Score reflects readiness without traction. |
| TOTAL | $1.95M | $2.50M | |
2.2 Scorecard Method (Bill Payne) — $4.11M
Compares to median pre-money valuation of funded health-tech startups ($3.5M baseline). Each factor scored as % of average. Baseline: $3.50M. Weighted multiplier: 1.175x.
| Factor | Weight | Score | Rationale |
|---|
| Management Team | 30% | 95% | Solo founder with extraordinary technical execution (built entire platform). Offset by lack of co-founder, no C-suite, no medical director yet. Score: 95% (slightly below average for solo-founder risk). |
| Size of Opportunity | 25% | 140% | $68B TAM growing 9.4% CAGR. FDA Category 1 reclassification is a once-in-a-decade regulatory tailwind. GLP-1 revolution proved the DTC prescription model. 77M Baby Boomers entering peak longevity demand. Score: 140% (well above average). |
| Product / Technology | 15% | 150% | Far beyond typical seed-stage prototype. 40+ production pages, 3 AI agents, genetic matching, predictive health, 14-source intelligence engine, dose tracking, biomarker dashboards, wearable integration, telemedicine, pharmacy fulfillment pipeline, community forum. Massive technical moat. Score: 150%. |
| Competitive Environment | 10% | 115% | No direct AI-first peptide platform competitor exists. Hims/Ro focused on GLP-1/hair/ED, not peptide protocol optimization. Anti-aging clinics lack technology. Research chem sites lack medical legitimacy. Score: 115%. |
| Marketing / Sales / Partnerships | 10% | 80% | Affiliate program built with MLM commission structure, lead capture active, SEO content infrastructure in place. However, no proven CAC or LTV data, no paying customers, no marketing spend history. Score: 80%. |
| Need for Additional Investment | 5% | 100% | Will need seed round for team, marketing, pharmacy inventory, and HIPAA certification. Standard capital requirements for this stage. Score: 100% (neutral). |
| Other Factors (IP, Timing, Regulatory) | 5% | 140% | Exceptional timing — post-FDA reclassification creates immediate legal clarity. First-mover advantage in AI-personalized peptide protocols. Proprietary AI agents and protocol intelligence engine represent defensible IP. Score: 140%. |
2.3 Risk Factor Summation — $4.50M
Adjusts baseline by ±$250K–$500K across 12 risk categories based on actual platform state and market conditions. Baseline: $3.50M.
| Risk Category | Adjustment | Rationale |
|---|
| Management Risk | $-250K | Solo founder — exceptional executor but single point of failure. Needs co-founder/C-suite. |
| Stage of Business | $-500K | Pre-revenue, pre-launch. Platform complete but no paying customers or revenue data. |
| Legislation / Political | +$500K | Major tailwind: FDA Category 1 reclassification (Feb 2026) legalizes compounded peptides through 503A pharmacies. |
| Manufacturing Risk | +$250K | Asset-light model — partners with FDA-registered 503A pharmacies. No in-house compounding liability. |
| Sales & Marketing Risk | $-250K | No proven CAC/LTV metrics. Affiliate program built but untested. Content/SEO infrastructure ready but unvalidated. |
| Funding / Capital Risk | $-250K | Bootstrapped to date. Will require institutional capital to scale team and marketing. No committed investors yet. |
| Technology Risk | +$500K | Platform is production-complete: 40+ pages, 30+ backend functions, 3 AI agents, Stripe integration, real-time data. Very low tech risk. |
| Litigation Risk | Neutral | Standard health-tech risk. Compliant disclaimers, consent tracking, and audit logging built in. Neutral. |
| International Risk | Neutral | US-only strategy. Coverage in 43+ states via IMLC. No international complexity. Neutral. |
| Reputation Risk | +$250K | Physician-prescribed model, GMP pharmacy partners, HIPAA compliance framework, consent tracking, and audit logging all build institutional trust. |
| Potential Lucrative Exit | +$500K | Digital health M&A averaging $7B+ annually. Hims at $3B+ market cap validates DTC health model. Strategic acquirer pool includes telehealth, pharma, and wellness platforms. |
| Competition Risk | +$250K | No direct competitor combines AI protocol optimization + physician prescribing + DTC delivery. Significant first-mover advantage. |
2.4 Venture Capital Method — $39.50M (Ceiling Signal Only)
Works backward from projected exit value to determine justified pre-money valuation today.
| Projected Year 6 Revenue | $85.00M |
| Industry Revenue Multiple | 10x (SaaS Health-Tech; peer range 8–15x) |
| Terminal / Exit Value | $850.00M |
| Target Seed ROI | 20x |
| Post-Money Valuation | $42.50M |
| Investment Amount | $3.00M |
| Implied Pre-Money | $39.50M |
Caveat: The VC Method produces a theoretical ceiling. Real-world seed rounds virtually never price at this level. Included for completeness only; excluded from round pricing rationale.
2.5 Cost-to-Duplicate — $3.27M
Floor valuation: what it would cost a team to rebuild the current platform from scratch at market rates.
| Component | Cost (USD) |
|---|
| Full-Stack Platform (40+ pages, 100+ components, 25 entities) | $850K |
| AI/ML Engine (3 agents, protocol optimizer, predictive health, genetic matching) | $500K |
| Backend Infrastructure (30+ serverless functions, real-time data, Stripe) | $350K |
| Admin Portal (doctor portal, pharmacy mgmt, order fulfillment, audit log) | $250K |
| Telemedicine & Video Consultation System | $200K |
| UI/UX Design & Frontend (dark theme, mobile-responsive, animations) | $200K |
| Medical & Compliance Framework (HIPAA, consent tracking, audit logging) | $250K |
| Community Forum & Social Features (posts, comments, voting, moderation) | $100K |
| Affiliate/MLM Program (multi-tier commissions, training, payouts) | $150K |
| Content & SEO Infrastructure (blog, guides, structured data, meta tags) | $100K |
| Pharmacy Partnership & Fulfillment Pipeline Development | $125K |
| Legal, Compliance, IP (terms, privacy, consent records, disclaimers) | $150K |
| Domain, Branding, Design System | $50K |
| TOTAL | $3.27M |
Part III — Investor Deck (9 Slides)
Slide 1 — Title
1yfe Health — The AI-Powered Peptide Therapy Platform
Physician-prescribed, AI-optimized peptide protocols delivered direct-to-patient. Full-stack platform with 40+ modules spanning e-commerce, telemedicine, AI health intelligence, and pharmacy fulfillment.
Seed Round · $3.00M Raise · Pre-Revenue (Platform Complete)
Slide 2 — The Problem: A $68B Market With Zero Intelligence
- Fragmented Access: Patients navigate sketchy research chemical sites or expensive anti-aging clinics with no personalization.
- No Data Integration: Biomarkers, wearables, genetics, and symptoms exist in silos. No platform connects them to optimize protocols.
- Regulatory Confusion: Post-FDA Category 1 reclassification, patients and providers don't know what's legal or how to access it.
- Cookie-Cutter Protocols: One-size-fits-all dosing ignores individual genetics, metabolic profiles, and response patterns.
Slide 3 — The Solution: AI-Personalized Peptide Protocols, End-to-End
- Protocol Intelligence Engine: 14-source AI brain ingests wearables, biomarkers, genetics, dose logs, and symptoms to generate and continuously optimize personalized protocols.
- Physician-Prescribed & Legal: Every protocol is reviewed and prescribed by IMLC-licensed physicians. Compounded by FDA-registered 503A pharmacies under USP 795/797.
- Predictive Health Intelligence: Machine learning detects patterns before they become problems and adjusts proactively.
- Full-Stack Platform (40+ Modules): E-commerce, subscriptions, telemedicine, dose tracking, wearable integration, community forum, affiliate MLM, admin portal — all built and live.
Slide 4 — Market Opportunity: $68B TAM at 9.4% CAGR
| Metric | Value | Description |
|---|
| TAM | $68B | Global peptide therapeutics |
| SAM | $12B | US longevity + anti-aging |
| SOM | $850M | DTC peptide protocols |
Catalysts: FDA Category 1 reclassification (Feb 2026); GLP-1 revolution proving DTC prescription model; longevity economy growing 17% annually; 77M Baby Boomers entering peak demand; wearable health data explosion; telemedicine adoption permanent post-COVID.
Slide 5 — Business Model: Multi-Revenue SaaS + Commerce Hybrid
| Stream | % of Revenue | Details |
|---|
| Subscription Revenue | 60% | 5 tiers from $199–$1,299/mo. Target 80%+ retention. |
| E-Commerce (One-Time) | 20% | Individual peptide products, lab kits, supplements. $79–$299 AOV. |
| Telemedicine Consults | 10% | $49–$199. Funnel to subscriptions. 40%+ conversion target. |
| B2B / Affiliate / Data | 10% | Enterprise wellness, affiliate commissions, data licensing. |
Unit Economics Target (Month 18)
| Blended ARPU | $420/mo |
| CAC | $185 |
| LTV | $7,560 |
| LTV:CAC Ratio | 40.9x |
Slide 6 — Traction: Built, Not Just Pitched
Completed ✓
- 40+ production pages, 100+ components, 25 database entities
- 30+ backend serverless functions (AI, payments, fulfillment, email)
- 3 AI agents: Protocol Optimizer, Intelligence Brain, Peptide Advisor
- 14-source Protocol Intelligence Engine with genetic matching
- Predictive Health AI, Bio Age calculator, wearable correlations
- Full e-commerce: Stripe checkout, cart, subscriptions ($199–$1,299/mo)
- Telemedicine system with video consultations & scheduling
- Admin portal: doctor workflow, pharmacy mgmt, order fulfillment, audit log
- Affiliate MLM program with multi-tier commissions & training
- Community forum, blog, SEO, consent tracking, HIPAA compliance framework
- FDA-registered 503A pharmacy partnerships, 43+ state coverage
Next →
- Seed round close → team expansion (CMO, COO)
- First 100 paying subscribers (Month 3-4)
- HIPAA-compliant data pipeline certification
- Series A readiness at $2M ARR
Slide 7 — Competitive Landscape
No direct AI-first peptide platform exists. 1yfe Health is the only offering combining AI protocol optimization, 14-source data integration, physician prescribing, genetic matching, predictive health AI, DTC e-commerce, subscription billing, and cold-chain delivery in a single integrated platform.
Slide 8 — The Ask: $3.00M Seed Round
| Pre-Money Valuation | $5.50M |
| Raise Amount | $3.00M |
| Post-Money Valuation | $8.50M |
| Investor Equity | ~35.29% |
Use of Funds
| Category | % | Amount |
|---|
| Engineering & AI | 35% | $1.1M |
| Sales & Marketing | 25% | $750K |
| Clinical & Compliance | 15% | $450K |
| Team Expansion | 15% | $450K |
| Operations & G&A | 10% | $300K |
| TOTAL | 100% | $3.00M |
Part IV — 6-Year Financial Model
Annual Projections (Base Case)
| Metric | Y1 | Y2 | Y3 | Y4 | Y5 | Y6 |
|---|
| Revenue | $420K | $3.2M | $12.5M | $32.0M | $58.0M | $85.0M |
| Subscribers | 85 | 520 | 2,100 | 5,200 | 9,500 | 14,200 |
| ARPU (blended) | $412 | $425 | $440 | $460 | $475 | $490 |
| CAC | $210 | $190 | $165 | $145 | $130 | $120 |
| Monthly Churn % | 8.5% | 6.2% | 4.8% | 4% | 3.5% | 3.2% |
| Gross Margin | 62% | 68% | 72% | 74% | 76% | 78% |
| OpEx | $2.1M | $3.8M | $8.5M | $18.0M | $29.0M | $38.0M |
| EBITDA | $-1.8M | $-1.6M | $500K | $5.7M | $15.1M | $28.3M |
| Headcount | 8 | 18 | 35 | 65 | 110 | 160 |
Year 1 Quarterly Ramp
| Quarter | Revenue | Total Subs | New Subs | Churned |
|---|
| Q1 | $15K | 8 | 8 | 0 |
| Q2 | $65K | 25 | 19 | 2 |
| Q3 | $140K | 52 | 32 | 5 |
| Q4 | $200K | 85 | 42 | 9 |
Revenue Mix (Steady State — Year 4+)
| Stream | % of Revenue |
|---|
| DTC Subscriptions | 40% |
| Provider SaaS | 20% |
| E-Commerce | 15% |
| Telemedicine | 8% |
| Certification | 7% |
| Data Licensing | 5% |
| B2B/Affiliate | 5% |
Scenario Analysis
| Scenario | Y6 Revenue | Exit Multiple | Exit Value |
|---|
| Base Case | $85M | 10x | $850M |
| Bull Case | $120M | 14x | $1.68B |
| Bear Case | $40M | 7x | $280M |
Sensitivity Analysis
| Driver | Base Impact | Exit Value Impact |
|---|
| Subscriber Growth +20% | +$17M Rev (Y6) | +$170M Exit Value |
| ARPU +$50/mo | +$8.5M Rev (Y6) | +$85M Exit Value |
| Churn -1% | +$4.2M Rev (Y6) | +$42M Exit Value |
| CAC -$30 | +$1.8M EBITDA | +$18M Exit Value |
| Gross Margin +5% | +$4.25M EBITDA | +$42.5M Exit Value |
Part V — Platform Audit Reference
Valuation is anchored to a live codebase audit:
| Production Pages | 47+ |
| Reusable Components | 110+ |
| Database Entities | 30 |
| Backend Serverless Functions | 35+ |
| AI Agents | 3 |
| Subscription Tiers | 5 ($199–$1,299/mo) |
| Revenue Streams (Configured) | 7 |
CONFIDENTIAL & FORWARD-LOOKING. This document contains confidential and proprietary information of 1YFE Inc. All financial projections, market estimates, and scenario analyses are forward-looking, based on management estimates and industry benchmarks, and are inherently uncertain. Actual results may differ materially. This document does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offer will be made solely pursuant to a formal offering document delivered to accredited investors in compliance with applicable securities laws (National Instrument 45-106 in Canada). Prospective investors should conduct independent due diligence and consult their own legal, tax, and financial advisors. The valuations herein are internal management valuations and do not constitute a formal appraisal by a Chartered Business Valuator (CBV).
© 2026 1YFE Inc. All rights reserved. · Ontario, Canada · Document Reference: 1YFE-BOD-EXH-2026-001-A